Also, novel IDO inhibitors, LW106 and NTRC 3883-0 inhibit tumor outgrowth in-vivo, limiting IDO-dependent stroma immune resistance and proliferation of cancer stem cells within the tumor microenvironment (Table 1) [94,95]. Here, IDO1 is linked to neoplasm.